Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients

Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients

Objective To investigate the clinical efficacy and prognosis of cross-line immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC).Methods Clinical data of patients with advanced NSCLC in Zhongnan Hospital of Wuhan University from June 2019 to December 2023 were retrospect...

Full description

Saved in:

Bibliographic Details
Main Authors:	WANG Yuankun, LU Jiahao, HU Jing, XIE Conghua
Format:	Article
Language:	zho
Published:	Editorial Office of New Medicine 2025-02-01
Series:	Yixue xinzhi zazhi
Subjects:	cross-line immunotherapy non-small cell lung cancer immune checkpoint inhibitors prognosis driver gene-negative
Online Access:	https://yxxz.whuznhmedj.com/futureApi/storage/attach/2502/SAsnnW97URWo1VKYsbGTX5O5s9AqUu0PGI4YdlBb.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy Versus Bevacizumab Combined with Chemotherapy in Advanced Driver Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
by: Chen W, et al.
Published: (2025-07-01)

Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge
by: Francesca Colonese, et al.
Published: (2024-11-01)

Immunotherapy for Extensive-stage Small Cell Lung Cancer:  Research Progress and Future Perspectives
by: Yuling ZHONG, et al.
Published: (2024-11-01)

Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer
by: Xinyue YANG, et al.
Published: (2025-05-01)

Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
by: Justin J. Kuhlman, et al.
Published: (2024-12-01)

Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions
by: Ryota Kikuchi, et al.
Published: (2025-12-01)

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
by: Antoine Desilets, MD, MSc, et al.
Published: (2024-12-01)

Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review
by: Yali Jin, et al.
Published: (2025-05-01)

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis
by: Lijuan Chen, et al.
Published: (2025-06-01)

Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response
by: Li Liu, et al.
Published: (2025-03-01)

Biomarkers for non-small cell lung cancer immunotherapy
by: D. A. Kharagezov, et al.
Published: (2021-09-01)

Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non‐Small‐Cell Lung Cancer Treated With Front‐Line Immunotherapy‐Based Therapies
by: Mingjia Li, et al.
Published: (2025-08-01)

Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
by: Lu Zheng, et al.
Published: (2025-01-01)

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
by: Emily Wolf, et al.
Published: (2025-01-01)

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer
by: Jing Cheng, et al.
Published: (2025-02-01)

Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer
by: Gopal P. Pathak, et al.
Published: (2024-10-01)

Efficacy and Safety of Perioperative Immunotherapy for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
by: Zhijuan Du, et al.
Published: (2025-03-01)

Advances in biomarkers for immunotherapy in small-cell lung cancer
by: Hui Li, et al.
Published: (2024-12-01)

Cerebral small vessel disease as a possibly immune-related adverse event of immunotherapy in lung cancer patients: a retrospective study
by: Na Wu, et al.
Published: (2025-08-01)

Efficiency in different immunotherapy of cancer: literature review
by: K. A. Gaptulbarova, et al.
Published: (2021-12-01)

Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach
by: Paweł Zieliński, et al.
Published: (2025-04-01)

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer
by: Xianqiang Liu, et al.
Published: (2024-12-01)

Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window
by: Kaibo Ding, et al.
Published: (2025-03-01)

Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer
by: Liuhua Long, et al.
Published: (2025-07-01)

First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes
by: Mengxing You, et al.
Published: (2025-06-01)

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
by: Guisen Yin, et al.
Published: (2025-01-01)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
by: Alain Vergnenegre, et al.
Published: (2020-01-01)

Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
by: Robert Pirker
Published: (2025-03-01)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China
by: Feng Chen, et al.
Published: (2025-05-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

Clinical Effect of Treatment with Metformin for Type 2 Diabetes on Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: A Retrospective Study
by: Wang Y, et al.
Published: (2024-12-01)

First‐line chemoimmunotherapy for patients with small‐cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis
by: Yu Li, et al.
Published: (2024-12-01)

Impact of duration of maintenance immunotherapy on the prognosis of locally advanced non-small cell lung cancer treated with chemoradiotherapy
by: HuiQi Fan, et al.
Published: (2025-07-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

Development of a prognostic model for patients with extensive-stage small cell lung cancer undergoing immunotherapy and chemotherapy
by: Yunbin Gao, et al.
Published: (2025-03-01)

Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis
by: Xinrong Chen, et al.
Published: (2025-05-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
by: Hong Huang, et al.
Published: (2025-04-01)

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
by: Huiping Qiang, et al.
Published: (2025-03-01)